Shares of Galapagos NV (NASDAQ:GLPG – Get Rating) have received an average recommendation of "Hold" from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $62.75.

Several equities research analysts have commented on the stock. Morgan Stanley cut shares of Galapagos from an "overweight" rating to an "equal weight" rating and cut their price target for the stock from $80.00 to $61.00 in a research report on Friday. Jefferies Financial Group cut shares of Galapagos from a "hold" rating to an "underperform" rating in a research report on Monday, July 25th. Finally, Royal Bank of Canada cut their price target on shares of Galapagos from $62.00 to $55.00 in a research report on Monday, August 8th.

Galapagos Price Performance

Shares of GLPG stock opened at $48.16 on Monday. Galapagos has a 12-month low of $46.41 and a 12-month high of $72.11. The firm has a fifty day moving average of $52.80 and a 200-day moving average of $57.55.

Institutional Investors Weigh In On Galapagos

A number of institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC raised its holdings in shares of Galapagos by 64.7% in the 2nd quarter. FMR LLC now owns 3,568,650 shares of the biotechnology company's stock valued at $199,131,000 after purchasing an additional 1,401,691 shares during the period. 683 Capital Management LLC grew its position in shares of Galapagos by 29.0% during the 4th quarter. 683 Capital Management LLC now owns 905,121 shares of the biotechnology company's stock worth $49,900,000 after purchasing an additional 203,700 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of Galapagos by 547.9% during the 4th quarter. Point72 Asset Management L.P. now owns 763,900 shares of the biotechnology company's stock worth $42,114,000 after acquiring an additional 646,000 shares in the last quarter. BlackRock Inc. boosted its position in shares of Galapagos by 46.8% during the 1st quarter. BlackRock Inc. now owns 517,611 shares of the biotechnology company's stock worth $32,103,000 after acquiring an additional 164,912 shares in the last quarter. Finally, Driehaus Capital Management LLC boosted its position in shares of Galapagos by 6.9% during the 2nd quarter. Driehaus Capital Management LLC now owns 510,649 shares of the biotechnology company's stock worth $28,494,000 after acquiring an additional 33,034 shares in the last quarter. 19.48% of the stock is owned by institutional investors.

About Galapagos

(Get Rating)

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis.

Recommended Stories

• Get a free copy of the StockNews.com research report on Galapagos (GLPG)
• Can Electronic Arts Buck the Downturn in Videogaming?
• Dollar General is the Big Fish in Little Ponds Across the U.S.
• Here's Why the CPI Report will Dictate the Market Bottom
• MarketBeat: Week in Review 9/5 – 9/9
• Prepare For A Record-Setting Quarter For Cyber Security Stocks

Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.